How India’s COVID-19 crisis became the worst in the world15 Jun, 2021
PUNE, India — Mohanish Ellitam watched helplessly as his 49-year-old mother’s oxygen levels dipped dangerously and she gasped for air. “I could see her stomach rising and falling,” Ellitam said. “I was so scared.”
Watching his mother’s health deteriorate, Ellitam knew he couldn’t wait any longer. But in Shevgaon, a small town in the state of Maharashtra, health care facilities were limited and already overwhelmed with people suffering from COVID-19. He frantically called ...
Pfizer COVID vaccine protects against worrying coronavirus variants12 May, 2021Data from Qatar provide strongest evidence yet that COVID-19 vaccines can stop strains thought to pose a threat to immunization efforts.
Qatar’s second wave of COVID-19 was a double whammy. In January, after months of relatively few cases and deaths, the Gulf nation saw a surge driven by the fast-spreading B.1.1.7 variant, which was first identified in the United Kingdom. Weeks later, the B.1.351 strain, which is linked to reinfections and dampened vaccine effectiveness, took hold.
FDA and CDC OK resuming J&J COVID-19 shots paused over rare clot concerns29 Apr, 2021Experts debated a warning for women under 50, but decided to reinstate the vaccine without oneJohnson & Johnson’s COVID-19 vaccine, which faced intense scrutiny in the wake of reports of women who developed rare blood clots after getting the shot, is OK to use, a panel of health experts decided April 23.PAUL HENNESSY/SIPA USA/ALAMY STOCK PHOTO
After reviewing safety data on rare blood clots linked to the Johnson & Johnson COVID-19 vaccine, federal regulators said vaccinations can r...
COVID-19 vaccines: Live updates29 Apr, 2021Household transmission reduced after first vaccine shot
A new study by Public Health England, which has not been peer-reviewed yet, indicates that people who have received one dose of the Pfizer-BioNTech or Oxford-AstraZeneca vaccine are 40–50% less likely to pass on the SARS-CoV-2 virus if they contract it.
The researchers looked at data from 365,447 households in which one person had a COVID-19 diagnosis. For each of these index cases, the team looked at whether any...
Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein24 Mar, 2021Abstract
Continued uncontrolled transmission of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in many parts of the world is creating the conditions for significant virus evolution1,2. Here, we describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance3–5. This lineage was ident...
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model15 Mar, 2021Abstract
The COVID-19 pandemic caused by the SARS-CoV-2 virus continually poses serious threats to global public health. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing Mpro inhibitors derived from either Boceprevir or Telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 Mpro activity in vitro with IC50 values ranging from 7.6 to 748.5 nM. The co-cr...
Can COVID vaccines stop transmission? Scientists race to find answers15 Mar, 2021
As countries roll out vaccines that prevent COVID-19, studies are under way to determine whether shots can also stop people from getting infected and passing on the SARS-CoV-2 virus. Vaccines that prevent transmission could help to bring the pandemic under control if they are given to enough people.
Preliminary analyses suggest that at least some vaccines are likely to have a transmission-blocking effect. But confirming that effect — and how strong it will be — is tricky because a ...
What you need to know about J&J’s newly authorized one-shot COVID-19 vaccine15 Mar, 2021
And then there were three: A single-shot vaccine is the latest weapon to join the battle against COVID-19 in the United States.
On February 27, the U.S. Food and Drug Administration gave emergency use authorization for Johnson & Johnson’s vaccine against SARS-CoV-2, the coronavirus that causes COVID-19. South Africa is the only other country to OK Johnson & Johnson’s vaccine so far, though other countries are poised to follow suit.
The FDA determined that Johnson &am...
More Than 159 Million Shots Given: Covid-19 Tracker12 Feb, 2021
The biggest vaccination campaign in history is underway. More than 159 million doses have been administered across 76 countries, according to data collected by Bloomberg. The latest rate was roughly 5.80 million doses a day.
In the U.S., more Americans have now received at least one dose than have tested positive for the virus since the pandemic began. So far, 48 million doses have been given, according to a state-by-...
Variant-proof vaccines — invest now for the next pandemic12 Feb, 2021COVID’s evolution signals the importance of rational vaccine design based on broadly neutralizing antibodies.
The rapid development and delivery of highly effective COVID-19 vaccines less than a year after the emergence of the disease is a huge success story. This was possible, in part, because of certain properties of the coronavirus SARS-CoV-2 that favour vaccine design — in particular, the spike protein on the virus’s surface. This prompts the body to make protective neutralizing an...
Vaccinemakers ponder how to adapt to virus variants2 Feb, 2021
News from U.S. manufacturer Moderna that its COVID-19 vaccine is still “expected to be protective” against a virus variant first detected in South Africa came as a relief to scientists and the public. But the 25 January announcement included a caveat: Antibodies triggered by the vaccine appear to be a little less potent against the new variant, named B.1.351, than the one the vaccine was developed for. So researchers were perhaps even more relieved to hear the company will start developme...
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial29 Jan, 2021
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
• Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination• 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28• Protection Against Severe Disease Acro...